Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

JPMorgan Removes Akero Therapeutics (AKRO) from Analyst Focus List and Catalyst Watch, PT $62

October 10, 2023 12:35 PM EDT

JPMorgan analyst Eric Joseph reiterated an Overweight rating and $62.00 price target on Akero Therapeutics (NASDAQ: AKRO).

The analyst comments "In our view, the totality of the SYMMETRY dataset continues to support EFX having a differentiated impact on histology across the spectrum of... More

Canaccord on Akero Therapeutics (AKRO): 'We would be strong buyers on this weakness'

October 10, 2023 8:21 AM EDT

Canaccord Genuity analyst Edward Nash reiterated a Buy rating and $59.00 price target on Akero Therapeutics (NASDAQ: AKRO)

The analyst comments "Akero Therapeutics reports 36-week analysis of SYMMETRY, a 96-week Phase IIb study evaluating the efficacy and safety of its lead product candidate efruxifermin... More

Cantor Fitzgerald on Akero Therapeutics (AKRO), 'we expect the stock to trade down'

October 10, 2023 7:55 AM EDT

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and $69.00 price target on Akero Therapeutics (NASDAQ: AKRO)

The analyst comments "EFX efficacy meets our mixed scenario, and we expect the stock to trade down (premarket stock is trading down 50%+, which seems an... More